



## Supplementary Materials



**Figure S1.** Cellular uptake of drug in damaged HUVEC cells. (A) Quantification of confocal microscopy images of intracellular FITC distribution in damaged HUVEC cells after FITC, FITC@DA-PLGA-PEG-cRGD NPs and FITC@DA-PLGA-PEG-cRGD NPs + US treatment for 1 and 4 h; (B) Flow cytometry analyses of damaged HUVEC cells incubated with FITC, FITC@DA-PLGA-PEG-cRGD NPs and FITC@DA-PLGA-PEG-cRGD NPs + US for 1 and 4 h. Data shown as mean  $\pm$  SD. ( $n = 3$ ). \*\*  $p < 0.001$ , \*  $p < 0.05$ .



**Figure S2.** Characterization of DA-PLGA-PEG NPs. (A) Particle size distribution of DA-PLGA-PEG NPs measured by DLS and weighted by intensity. (B) Apparent zeta potential of DA-PLGA-PEG NPs observed.